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ABSTRACT
Objective To evaluate the test performance of 47
biomarkers and ultrasound parameters for the prediction
of delivery of a small-for-gestational-age (SGA) infant
and adverse perinatal outcome in women presenting with
suspected pre-eclampsia.
Methods This was a prospective, multicenter observa-
tional study in which 47 biomarkers and ultrasound
parameters were measured in 397 women with a sin-
gleton pregnancy presenting with suspected preterm
pre-eclampsia between 20 + 0 and 36 + 6 weeks’ gesta-
tion, with the objective of evaluating them as predictors
of subsequent delivery of a SGA infant and adverse peri-
natal outcome. Women with confirmed pre-eclampsia at
enrollment were excluded. Factor analysis and stepwise
logistic regression were performed in two prespecified
groups stratified according to gestational age at enroll-
ment. The primary outcome was delivery of a SGA infant
with a birth weight < 3rd customized centile (SGA-3),
and secondary outcomes were a SGA infant with a birth
weight < 10th customized centile and adverse perinatal
outcome.
Results In 274 women presenting at 20 + 0 to 34 + 6
weeks’ gestation, 96 (35%) delivered a SGA-3 infant.
For prediction of SGA-3, low maternal placental growth
factor (PlGF) concentration had a sensitivity of 93%
(95% CI, 84–98%) and negative predictive value (NPV)
of 90% (95% CI, 76–97%) compared with a sensitivity
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of 71% (95% CI, 58–82%) and a NPV of 79% (95%
CI, 68–87%) for ultrasound parameters (estimated fetal
weight or abdominal circumference < 10th centile). No
individual biomarker evaluated had a better performance
than did PlGF, and marker combinations made only small
improvements to the test performance. Similar results
were found in 123 women presenting between 35 + 0 and
36 + 6 weeks’ gestation.
Conclusion In women presenting with suspected preterm
pre-eclampsia, measurement of PlGF offers a useful
adjunct for identifying those at high risk of delivering
a SGA infant, allowing appropriate surveillance and
timely intervention. © 2017 The Authors. Ultrasound
in Obstetrics & Gynecology published by John Wiley
& Sons Ltd on behalf of the International Society of
Ultrasound in Obstetrics and Gynecology.
INTRODUCTION
Infants who are born small-for-gestational age (SGA) are
at increased risk of short-term neonatal morbidity and
mortality1–3, and longer-term complications extending
into adult life, including cardiovascular disease and
Type-II diabetes mellitus4. SGA is commonly defined
as birth weight under a centile threshold. For infants
under the 10th centile of the population, this group
includes constitutionally small infants and those with fetal
growth restriction, the latter defined as failure of a fetus
to reach its full growth potential. Use of birth-weight
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centiles customized for additional maternal (height,
weight, ethnicity, parity) and fetal (sex) variables improves
identification of those fetuses at risk of adverse perinatal
outcome, including stillbirth and neonatal death5.
The underlying pathophysiology of fetal growth
restriction is complex, but poor placentation plays a key
role in a substantial proportion of SGA, particularly in
women with preterm hypertensive disorders and when
associated with adverse perinatal outcome. There is
a need for a test in the second half of pregnancy
to identify those at highest risk of delivering a SGA
infant. Markers of placental function could offer a
useful adjunct to current ultrasonographic techniques
to improve risk stratification, enabling identification
of those at greatest risk and minimizing unnecessary
interventions in lower-risk women. Several biomarkers
have been suggested as potential predictors of fetal
growth restriction, but to date none has been shown
to have adequate accuracy to support incorporation into
clinical practice6. The fetuses of women with suspected
hypertensive disorders of pregnancy who present before
37 weeks’ gestation are at increased risk of fetal growth
restriction, but the optimal strategy for identifying such
fetuses remains unclear.
As part of a large prospective study in women pre-
senting with suspected pre-eclampsia (PE), we sought first
to evaluate 47 biomarkers (identified by an extensive lit-
erature search) and then compare the best performing
biomarker(s) against currently utilized ultrasound param-
eters for determining subsequent delivery of a SGA infant
and adverse perinatal outcome.
METHODS
The PELICAN study was a prospective observational
study, undertaken between January 2011 and February
2012 in seven consultant-led maternity units in the UK
and Ireland. The role of placental growth factor (PlGF)
in determining the need for delivery within 14 days
of sampling for PE in this study has been reported
previously7, and this was a planned further analysis.
Participants
Study eligibility required the presence of signs or symp-
toms of suspected PE in women presenting between
20 + 0 and 36 + 6 weeks’ gestation with a single-
ton pregnancy and aged ≥ 16 years; women with
confirmed PE at enrollment were excluded. Written
informed consent was obtained and baseline demo-
graphic and pregnancy-specific data were entered
into the study database. Blood was drawn into
ethylenediamine-tetraacetic acid at study enrollment and
samples were centrifuged at 3000 rpm for 10 min. Plasma
was extracted and stored at –80◦C until analysis. Man-
agement of the women in the study followed the usual
care pathways for women with suspected PE, as advised in
the UK National Institute for Health and Care Excellence
‘Hypertension in Pregnancy’ guidelines8, with ultrasound
assessment being undertaken as clinically indicated.
Ultrasound assessments were undertaken by trained
ultrasonographers at each study site as clinically indicated,
using a variety of machines and following local
protocols for the measurement of fetal biometry, amniotic
fluid index and umbilical artery Doppler flow-velocity
waveforms (as occurred in clinical practice at the time of
the study). Quality control was undertaken through local
procedures rather than by the research team centrally.
Estimated fetal weight (EFW) was calculated at each
site using the Hadlock formula9. Additional parameters,
including uterine artery, fetal middle cerebral artery and
ductus venosus Doppler studies, were not universally
reported and therefore their performance could not
be compared with biomarker performance. As study
sites were reporting abnormal ultrasound assessment
using a variety of parameters (including abdominal
circumference (AC) and EFW < 10th, < 5th and < 3rd
centiles), the most commonly reported parameter, AC or
EFW < 10th centile, was chosen to enable comparison
across sites. The presence of AC or EFW < 10th centile,
oligohydramnios (amniotic fluid index < 5th centile)
or absent/reversed end-diastolic flow was recorded by
participating midwives.
Final diagnoses of maternal hypertensive disorders of
pregnancy were assigned, following agreement by an
adjudication panel of experts, using definitions from the
American College of Obstetricians and Gynecologists
practice bulletin10. SGA was defined as birth weight
< 3rd customized centile (SGA-3), with birth weight
< 10th customized centile (SGA-10) being a secondary
outcome, calculated using the Gestation-Related Optimal
Weight (GROW) method by freely available software11.
All diagnoses were assigned without knowledge of any
biomarker values.
The prespecified first part of the biomarker analysis
presented here relates to two groups of women in pre-
defined gestational age strata enrolled with a singleton
pregnancy and suspected preterm PE: Group 1 at 20 + 0
to 34 + 6 weeks’ gestation and Group 2 at 35 + 0 to
36 + 6 weeks’ gestation. For comparison with ultrasound
parameters, the second part of the analysis was restricted
to women with an ultrasound scan performed within
14 days of blood sampling at enrollment. The princi-
pal prespecified outcome of both analyses was delivery
of a SGA-3 infant3. The prespecified secondary outcome
measures were birth weight < 10th customized centile
(SGA-10) and adverse perinatal outcome. Adverse perina-
tal outcome was predefined as the presence of any of the
following complications: antepartum/intrapartum fetal or
neonatal death, intraventricular hemorrhage, periventric-
ular leukomalacia, seizure, retinopathy of prematurity,
respiratory distress syndrome, bronchopulmonary dys-
plasia, necrotizing enterocolitis or admission to neonatal
unit for > 48 h at term. Adverse maternal outcome was
defined as the presence of any of the following: mater-
nal death, eclampsia, stroke, cortical blindness or retinal
detachment, hypertensive encephalopathy, systolic blood
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pressure ≥ 160 mmHg, myocardial infarction, intubation
(other than for Cesarean section), pulmonary edema,
platelets < 50 × 109/L (without transfusion), dissemi-
nated intravascular coagulation, thrombotic thrombo-
cytopenic purpura/hemolytic uremic syndrome, hepatic
dysfunction (alanine transaminase ≥ 70 IU/L), hepatic
hematoma or rupture, acute fatty liver of pregnancy, cre-
atinine > 150μmol/L, renal dialysis, placental abruption,
major postpartum hemorrhage or major infection.
Biomarker measurement
An initial panel of biomarkers was selected based on
a-priori knowledge of an association with PE, a biologi-
cal role in placentation or a role in cellular mechanisms
involved in the pathogenesis of PE, e.g. angiogenesis,
inflammation, coagulation. The full list of 47 biomarkers,
measured with 57 assays (in which potentially biologi-
cally important assays of different epitope specificity were
available) was generated following a review of the litera-
ture, appraisal of selected bibliography and consultation
with medical experts (Table S1).
Samples were labeled and transported to the laboratory,
where they were spun at 3000 rpm for 10 min. Plasma
samples were tested for PlGF using the Triage PlGF Test
(Alere Inc., San Diego, CA, USA) by trained laboratory
staff at the study site where the sample was taken (as
previously published). The additional 56 biomarker assays
were analyzed in a central laboratory facility (Alere, San
Diego, CA, USA) and full details of assay methods are
given in Appendix S1 and Table S2. All participants
were delivered and pregnancy outcomes recorded before
biomarker concentrations were analyzed and revealed,
and all laboratory staff were blinded to clinical outcomes.
Statistical analysis
Standard distributional checks showed high levels of
skewness for all 57 assays, which were consistent with
underlying values of log normal distribution. Logged
values of these biomarkers were therefore used. Before
considering the pregnancy outcomes, statistical factor
analysis of biomarker data was undertaken, reducing the
47 biomarkers into a smaller number of highly correlated
groups, solely on the basis of the correlations between the
biomarkers. Factor summary scores were then calculated
for all the women. Consideration of scree plots and
eigenvalues (> 2) identified the most important factors for
further analysis12. These factors were rotated (orthogonal
varimax method) so that each factor related strongly
(correlation > 0.6) to a small number of biomarkers only
(factor analysis displayed in Table S3).
The factor scores were entered into a multiple logistic
regression model for prediction of subsequent SGA. Two
factors (and their biomarkers), with significant odds ratios
for prediction of SGA < 3rd centile, were identified for
further investigation (Tables S4 and S5). Stepwise logistic
regression was used to determine which biomarkers
appeared to provide additional information beyond that
derived from PlGF, and prediction scores were extracted
for the best combinations. A comparison of areas under
the receiver–operating characteristics curves (AUCs) of
individual biomarkers and combinations was made to see
if any of the additional information was both consistent
and clinically useful. Significance was assessed through
the use of a non-parametric test, which allowed for
non-independence of observations on the same partici-
pant, with Bonferroni correction for multiple testing.
Some biomarkers, with high uniqueness scores, were
not strongly associated with any factor. To investigate
whether any of these biomarkers had prognostic power
in addition to that provided by PlGF and biomarkers
identified earlier, stepwise logistic regression analysis was
undertaken.
The best performing biomarker was then assessed using
standard test performance indices (sensitivity, specificity,
predictive values and AUC) against currently utilized
ultrasound parameters in the subgroup of women with
an ultrasound scan within 14 days of blood sampling, for
the prediction of SGA and adverse perinatal outcome. A
sensitivity analysis was conducted excluding those fetuses
in which the scan on the day of enrollment had abnormal
findings (AC or EFW < 10th centile, oligohydramnios or
absent/reversed end diastolic flow (n = 20)).
Statistical analysis was carried out in the statistical
package Stata version 11.2 (College Station, TX, USA);
statistical significance was taken as P < 0.05. The prespec-
ified sample size was calculated for accurate estimation of
the sensitivity (within 10%) and specificity (within 6%)
of a biomarker, assuming a sensitivity of 0.90, specificity
of 0.90 and two-tailed 95% CIs, for determining the
primary endpoint; this required 62 patients with PE and
150 women not meeting the primary endpoint.
The study is reported in accordance with Strengthening
the Reporting of Observational Studies in Epidemiology
guidelines (Table S6)13, it was approved by East London
Research Ethics Committee (ref. 10/H0701/117) and it
followed institutional guidelines.
RESULTS
Between January 2011 and February 2012, 274 women
presenting with suspected PE and a singleton pregnancy
were enrolled between 20 + 0 and 34 + 6 weeks’ gestation
(Group 1), and 123 women were enrolled between 35 + 0
and 36 + 6 weeks (Group 2) (Figure 1).
The characteristics of the women in Group 1 at booking
and enrollment are shown in Table 1 and details of
maternal and neonatal outcomes are given in Table 2.
Of the 274 women in Group 1, 96 (35%) delivered
a SGA infant < 3rd centile (SGA-3) (of whom 90%
developed PE) and 130 (47%) delivered a SGA infant
< 10th centile (of whom 81% developed PE). Adverse
perinatal outcome was three times higher (39% vs 13%)
in cases complicated by SGA-3 than in those delivering an
infant with appropriate-for-gestational-age birth weight.
Stillbirth occurred in six pregnancies, in five of which the
birth weight was < 3rd centile. In all stillbirth cases the
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Recruited before
37 weeks’ gestation
(n = 423)
Multiple pregnancy
excluded (n = 26)
Considered for study
(n = 397)
Enrolled between
20 + 0 and 34 + 6 weeks
(n = 274)
Enrolled between
35 + 0 and 36 + 6 weeks
(n = 123)
No ultrasound scan, amniotic
 fluid index or umbilical artery
 Doppler data available (n = 24)
Ultrasound scan and PlGF sample
 >14 days apart (n = 46)
No ultrasound scan, amniotic
 fluid index or umbilical artery
 Doppler data available (n = 50)
Ultrasound scan and PlGF sample
 >14 days apart (n = 95)
Ultrasound scan and PlGF
measurement within or
at 14 days (full data)
(n = 129)
Ultrasound scan and PlGF
measurement within or
at 14 days (full data)
(n = 53)
SGA <10th centile
(n = 21)
BW ≥10th centile
(n = 32)
SGA <3rd centile
(n = 62)
SGA <3rd centile
(n = 14)
BW ≥10th centile
(n = 52)
SGA <10th centile
(n = 77)
Figure 1 Flowchart of study participants. BW, birth weight; PlGF, placental growth factor; SGA, small-for-gestational age.
Table 1 Characteristics of 274 women presenting at 20 + 0 to 34 + 6 weeks’ gestation with suspected pre-eclampsia (PE), according to
subsequent birth weight of infant
Characteristic
Women with SGA infant
< 3rd centile (n = 96)
Women with SGA infant
< 10th centile (n = 130)
Women with infant
≥ 10th centile (n = 144)
At booking
Age (years) 31.9 (27.2–36.2) 31.9 (27.4–36.4) 31.7 (26.3–35.6)
BMI (kg/m2) 26.8 (24.1–31.2) 28.0 (23.9–32.8) 29.3 (24.7–34.9)
White ethnicity 63 (66) 87 (67) 92 (64)
Highest systolic BP (mmHg) 120 (110–130) 121 (110–130) 120 (110–130)
Highest diastolic BP (mmHg) 74 (65–81) 74 (65–81) 75 (68–82)
Smoker at booking 17 (18) 24 (18) 29 (20)
Quit smoking during pregnancy 10 (10) 14 (11) 19 (13)
Previous PE requiring delivery < 34 weeks 15 (16) 18 (14) 12 (8)
Chronic hypertension 11 (11) 21 (16) 23 (16)
At enrollment
GA at sampling (weeks) 31.0 (27.6–33.0) 31.0 (27.6–33.1) 31.1 (28.0–33.6)
New-onset hypertension 60 (63) 80 (62) 65 (45)
Worsening of underlying hypertension 16 (17) 24 (18) 32 (22)
New-onset dipstick proteinuria 58 (60) 79 (61) 71 (49)
Highest systolic BP (mmHg) 147 (137–160) 148 (138–160) 141 (128–156)
Highest diastolic BP (mmHg) 94 (83–100) 94 (83–100) 90 (80–100)
Values given as median (interquartile range) or n (%). BMI, body mass index; BP, blood pressure; GA, gestational age; SGA, small-for-
gestational age.
PlGF concentration was < 5th centile at enrollment, and
predated the detection of ultrasound abnormalities by 7 to
39 days and the occurrence of stillbirth by 10 to 53 days.
The predictive performance of the most promising
biomarkers as depicted by AUCs is shown in Table 3;
AUCs for all 47 biomarkers measured are given in Table
S7, and individual median biomarker concentrations in
women sampled prior to 35 weeks are shown in Table
S8. In isolation, PlGF had the best predictive performance
for the detection of SGA-3 when measured before 35
weeks’ gestation, with an AUC of 0.83 (sensitivity,
89.7% (95% CI, 81.7–94.9%); specificity, 58.7% (95%
CI, 51.1–66.0%); positive predictive value, 53.8%
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Table 2 Delivery characteristics and maternal and neonatal outcome of 274 women presenting at 20 + 0 to 34 + 6 weeks’ gestation with
suspected pre-eclampsia (PE), according to subsequent birth weight of infant
Characteristic
Women with SGA infant
< 3rd centile (n = 96)
Women with SGA infant
< 10th centile (n = 130)
Women with infant
≥ 10th centile (n = 144)
Onset of labor*
Spontaneous 3 (3) 7 (5) 32 (22)
Induced 29 (30) 42 (32) 64 (44)
Prelabor Cesarean section 64 (67) 80 (62) 46 (32)
Mode of delivery*
Spontaneous vaginal 15 (16) 25 (19) 45 (31)
Assisted vaginal 5 (5) 8 (6) 21 (15)
Cesarean section 75 (78) 95 (73) 78 (54)
Adverse maternal outcome† 44 (46) 61 (47) 56 (39)
GA at delivery (weeks) 33.8 (30.8–36.1) 34.4 (31.4–37.3) 38.1 (36.0–39.4)
Fetal death 5 (5) 5 (4) 1 (1)
Neonatal death 2 (2) 2 (2) 0 (0)
Birth weight (g) 1537 (1043–1910) 1660 (1200–2310) 3128 (2698–3545)
SGA < 10th birth-weight centile 96 (100) 130 (100) 0 (0)
SGA < 3rd birth-weight centile 96 (100) 96 (74) 0 (0)
SGA < 1st birth-weight centile 68 (71) 68 (52) 0 (0)
Adverse perinatal outcome† 37 (39) 41 (32) 19 (13)
Maternal diagnosis
No disease 0 (0) 1 (1) 21 (15)
Gestational hypertension 1 (1) 1 (1) 25 (17)
Chronic hypertension 4 (4) 12 (9) 16 (11)
PE 86 (90) 106 (82) 59 (41)
HELLP syndrome 1 (1) 1 (1) 1 (1)
Other 4 (4) 9 (7) 22 (15)
Values given as median (interquartile range) or n (%). *Data missing for onset of labor in one woman and mode of delivery in two.
†Adverse outcome defined in main text. GA, gestational age; SGA, small-for-gestational age.
(95% CI, 45.7–61.7%); and negative predictive value
(NPV), 91.3% (95% CI, 84.6–95.8%)). Combinations
of the most promising biomarkers (Table 3) showed
only minimal non-significant increases in AUC for the
prediction of SGA-3 (from 0.83 to 0.84) and SGA-10
(from 0.79 to 0.80).
Of women enrolled before 35 weeks, 129 had an
ultrasound scan with all parameters recorded within 14
days of enrollment. The test performances of ultrasound
parameters and PlGF (the best performing biomarker)
for determining SGA-3 and SGA-10 are shown in Table 4
and Table S9, respectively, with PlGF alone having a
higher sensitivity (SGA-3, 93% (95% CI, 84–98%))
and NPV (SGA-3, 90% (95% CI, 76–97%)) than any
other indicator. While the addition of PlGF to currently
used ultrasound parameters (AC or EFW < 10th centile)
increased the sensitivity for the detection of SGA-3 (from
71% to 97%), the addition of ultrasound parameters to
PlGF measurement did not markedly enhance sensitivity
(from 93% to 97%). Adverse perinatal outcome (exclud-
ing SGA in this definition) occurred in 22% (60 of
274 infants). In predicting composite adverse perinatal
outcome, PlGF had the highest sensitivity (90%) and
NPV (90%) compared with all ultrasound measurements
(n = 129; Table 5). In a sensitivity analysis, performance
of the ultrasound and PlGF variables was similar when
those with an abnormal scan on the day of enrollment
were excluded from the analysis (Tables S10 and S11).
A total of 123 women were enrolled between 35 + 0
and 36 + 6 weeks’ gestation (Group 2); characteristics of
these women at booking and enrollment and details of
maternal and neonatal outcomes are described in Tables
S12 and S13. AUCs for all 47 biomarkers measured
between 35 + 0 and 36 + 6 weeks are given in Table
S14. When measured in isolation, PlGF had an AUC of
0.69 for predicting SGA-3 and 0.74 for SGA-10; addition
of carboxypeptidase A4 raised this to 0.77 for SGA-3
and 0.81 for SGA-10 (Table S15). The addition of other
biomarkers yielded little benefit. In this group, PlGF had a
higher sensitivity than all other currently used ultrasound
indicators in predicting SGA infants (Tables S16 and S17)
and adverse perinatal outcomes (Table S18).
DISCUSSION
Our study shows that PlGF measurement has a high
sensitivity and NPV in the determination of subsequent
delivery of a SGA infant, and in the prediction of adverse
perinatal outcome, in women presenting with suspected
preterm PE. We evaluated SGA < 3rd birth-weight centile
to identify fetuses more likely to be growth restricted,
rather than constitutionally small. Our study suggests
that PlGF measurement has a potential role alongside
ultrasound assessment in the surveillance of high-risk
women with suspected PE and that integration of
PlGF with current ultrasound parameters may increase
detection rates of SGA. Ultrasound has an essential role in
the detection of falling growth velocity, oligohydramnios
and abnormal umbilical artery Doppler waveforms, which
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Table 3 Performance of individual biomarkers and their combinations (derived from logistic regression analysis) for prediction of
small-for-gestational-age (SGA) < 3rd centile and < 10th centile in 274 women presenting at 20 + 0 to 34 + 6 weeks’ gestation with suspected
pre-eclampsia (PE)
AUC (95% CI)
Biomarker SGA < 3rd centile SGA < 10th centile P*
Nephrin 0.63 (0.56–0.70) 0.62 (0.55–0.69) < 0.001
CPA-4† 0.63 (0.57–0.70) 0.62 (0.55–0.68) < 0.001
sFlt-1 0.73 (0.67–0.79) 0.69 (0.63–0.76) < 0.001
Endoglin 0.74 (0.68–0.80) 0.73 (0.67–0.79) < 0.001
PlGF† 0.83 (0.78–0.88) 0.79 (0.73–0.84) —
PlGF/s-Flt ratio† 0.80 (0.75–0.85) 0.77 (0.71–0.82) 0.004
PlGF/endoglin ratio† 0.82 (0.77–0.86) 0.78 (0.73–0.83) 0.204
PlGF† + CPA-4† 0.83 (0.78–0.88) 0.79 (0.74–0.84) 0.560
PlGF† + nephrin 0.84 (0.79–0.88) 0.80 (0.74–0.85) 0.475
PlGF† + nephrin + CPA-4† 0.84 (0.79–0.89) 0.80 (0.74–0.85) 0.390
*Comparison of performance of single biomarker (or combination) vs placental growth factor (PlGF) alone. †Low concentration of
biomarker or low ratio correlates to disease. AUC, area under receiver–operating characteristics curve; CPA-4, carboxypeptidase A4; sFlt-1,
soluble fms-like tyrosine kinase-1.
Table 4 Performance of individual indicators and their combinations for prediction of small-for-gestational-age (SGA) < 3rd customized
birth-weight centile in 129 women presenting at 20 + 0 to 34 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound
examination within 14 days of enrollment
Indicator
Sensitivity
(95% CI) (%)
Specificity
(95% CI) (%)
PPV
(95% CI) (%)
NPV
(95% CI) (%)
LR+
(95% CI)
LR−
(95% CI)
Indicator in isolation
AC or EFW < 10th centile 71.2
(57.9–82.2)
92.5
(83.4–97.5)
89.4
(76.9–96.5)
78.5
(67.8–86.9)
9.5
(4.0–22.5)
0.31
(0.21–0.47)
Oligohydramnios* 18.6
(9.7–30.9)
98.5
(92.0–100.0)
91.7
(61.5–99.8)
57.9
(48.3–67.1)
12.5
(1.7–93.9)
0.83
(0.73–0.94)
AREDF 20.3
(11.0–32.8)
98.5
(92.0–100.0)
92.3
(64.0–99.8)
58.4
(48.8–67.6)
13.6
(1.8–101.7)
0.81
(0.71–0.92)
PlGF < 100 pg/mL 93.2
(83.5–98.1)
52.2
(39.7–64.6)
63.2
(52.2–73.3)
89.7
(75.8–97.1)
2.0
(1.5–2.5)
0.13
(0.05–0.34)
Combinations of indicators
AC or EFW < 10th centile
or oligohydramnios or
AREDF
72.9
(59.7–83.6)
91.0
(81.5–96.6)
87.8
(75.2–95.4)
79.2
(68.5–87.6)
8.1
(3.7–17.7)
0.30
(0.19–0.46)
AC or EFW < 10th centile
or PlGF < 100 pg/mL
96.6
(88.3–99.6)
49.3
(36.8–61.8)
62.6
(51.9–72.6)
94.3
(80.8–99.3)
1.9
(1.5–2.3)
0.07
(0.02–0.28)
*Oligohydramnios defined as amniotic fluid index < 5th centile for gestational age. AC, abdominal circumference; AREDF, absent or
reversed end-diastolic flow in umbilical artery; EFW, estimated fetal weight; LR+/LR−, positive/negative likelihood ratio; NPV, negative
predictive value; PlGF, placental growth factor; PPV, positive predictive value.
will continue to be used to stratify surveillance and time
delivery appropriately. The use of PlGF for the prediction
of SGA relates to this high-risk group of women with
suspected PE and cannot be generalized to low-risk
healthy pregnant women14.
Of 46 additional biomarkers evaluated in isolation or
in combination with PlGF, there was minimal added value
to the predictive performance of PlGF alone, and these
markers are unlikely to be of utility in the clinical setting.
It is possible that serial PlGF concentrations, with mea-
surements made closer to outcome, may further improve
the predictive ability while other biomarkers may only
become significant closer to outcome. Placental pathology
would have been a useful additional tool for assessing fetal
growth restriction, but it was not available for this study.
A possible source of intervention bias is that ultrasound
results were revealed to clinicians while biomarker results
were not. At the time of the study in the UK, it was not
common practice to deliver for falling growth velocity
alone (i.e. pre-empting delivery of a SGA infant) unless
the EFW fell below the < 10th centile. Adverse perinatal
outcome (excluding SGA) was chosen as a secondary
outcome to evaluate the performance of the variables on
this additional clinically meaningful endpoint.
This study enrolled women who presented for obstetric
assessment with a broad range of symptoms and signs of
suspected PE, including those with underlying maternal
disease. This is more informative than evaluating the
tests against normal healthy pregnant women (as in
a case–control study), as it is likely to reflect more
closely the test performance in the usual clinical setting.
The multicenter nature of the study, incorporating
women of geographic and ethnic diversity, adds to the
generalizability of the results. Further strengths of the
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Table 5 Performance of individual indicators and their combinations for prediction of adverse perinatal outcome in 129 women presenting
at 20 + 0 to 34 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound examination within 14 days of enrollment
Indicator
Sensitivity
(95% CI) (%)
Specificity
(95% CI) (%)
PPV
(95% CI) (%)
NPV
(95% CI) (%)
LR+
(95% CI)
LR−
(95% CI)
Indicator in isolation
AC or EFW < 10th centile 48.7
(32.4–65.2)
67.8
(56.9–77.4)
40.4
(26.4–55.7)
74.7
(63.6–83.8)
1.5
(1.0–2.4)
0.76
(0.54–1.06)
Oligohydramnios* 12.8
(4.3–27.4)
92.0
(84.1–96.7)
41.7
(15.2–72.3)
70.2
(60.9–78.4)
1.6
(0.5–4.7)
0.95
(0.83–1.09)
AREDF 12.8
(4.3–27.4)
90.8
(82.7–95.9)
38.5
(13.9–68.4)
69.9
(60.6–78.2)
1.4
(0.5–4.0)
0.96
(0.84–1.10)
PlGF < 100 pg/mL 89.7
(75.8–97.1)
40.2
(29.9–51.3)
40.2
(29.9–51.3)
89.7
(75.8–97.1)
1.5
(1.2–1.8)
0.25
(0.10–0.67)
Combinations of indicators
AC or EFW < 10th centile
or oligohydramnios or
AREDF
53.8
(37.2–69.9)
67.8
(56.9–77.4)
42.9
(28.8–57.8)
76.6
(65.6–85.5)
1.7
(1.1–2.6)
0.68
(0.47–0.98)
AC or EFW < 10th centile
or PlGF < 100 pg/mL
92.3
(79.1–98.4)
36.8
(26.7–47.8)
39.6
(29.5–50.4)
91.4
(76.9–98.2)
1.5
(1.2–1.8)
0.21
(0.07–0.64)
*Oligohydramnios defined as amniotic fluid index < 5th centile for gestational age. AC, abdominal circumference, AREDF, absent or
reversed end-diastolic flow in umbilical artery; EFW, estimated fetal weight; LR+/LR−, positive/negative likelihood ratio; NPV, negative
predictive value; PlGF, placental growth factor; PPV, positive predictive value.
study are that all final clinical diagnoses were adjudicated
by a panel of medical experts and all clinical and
laboratory staff were unaware of biomarker results until
completion of the study.
It is a feature of our study that the assessments (includ-
ing ultrasound examination) were performed in a local
healthcare setting without referral, ultrasound or man-
agement protocols being dictated centrally by the research
team. It is a strength that this pragmatic approach makes
it likely that the prognostic variables would have compa-
rable performance when translated beyond the research
setting, with the findings directly generalizable to similar
healthcare settings. However, it is a potential limitation
that such an approach does not reflect assessment of
ultrasound as undertaken in some healthcare systems
(e.g. by a maternal–fetal medicine subspecialist).
The findings of this study relate to similar health-
care settings in which same-day ultrasound assessment
is not routinely undertaken for women presenting with
suspected PE, owing to national guideline recommenda-
tions or lack of trained ultrasonographers. In settings in
which all women with suspected PE undergo same-day
ultrasound assessment by a maternal–fetal medicine sub-
specialist, the performance of ultrasound may be different.
As we included scans performed within 14 days after
blood sampling, ultrasound scans may have been under-
taken closer to the clinical endpoint (and would therefore
not have been expected to introduce bias against ultra-
sound test performance).
We are not aware of any study that has compared such
a wide panel of biomarkers (n = 47) for the prediction
of subsequent SGA in women with suspected PE. Reports
on the capability of PlGF to predict SGA have been
conflicting. Initial small case–control studies in the first
and second trimesters for the prediction of SGA found
no significant relationship15,16, but subsequent larger
case–control studies and several prospective cohorts
measuring PlGF in the second and first trimesters have
reported an association between low PlGF concen-
trations and early-onset pre-eclampsia17,18, stillbirth19
and SGA20–22. The few small (n = 21 or fewer),
mainly case–control studies in which measurement was
undertaken in the third trimester (including at time of
delivery), generally concur with our finding of low PlGF
concentration in women with subsequent delivery of
a SGA infant23–26, particularly those with significant
underlying placental pathology27. As impaired placental
function underpins a substantial proportion of cases of
SGA (and PE)28, an angiogenic placental factor such as
PlGF has biological plausibility for prediction. A recent
systematic review of 53 studies (principally of first- and
second-trimester prediction, and with no studies of PlGF
in a similar cohort to this study) investigated the value of
biomarkers in the prediction of fetal growth restriction in
singleton pregnancies and concluded that PlGF emerged
as the most promising of the 37 biomarkers reported6.
The finding that PlGF measurements also predict adverse
perinatal outcome is supported by two other studies29,30,
but the first evaluated PlGF measurements in the first
trimester while the second reported a combined maternal
and perinatal adverse outcome.
SGA has the highest population-attributable risk value
(23%) for stillbirth of all pregnancy-specific disorders31.
In this study cohort, five of six cases complicated
by stillbirth delivered an infant with a birth weight
< 3rd centile. In a setting in which ultrasound is not
routinely performed in all women with suspected PE, PlGF
measurement might facilitate earlier and more accurate
detection of SGA associated with perinatal mortality,
allowing appropriate surveillance of those at highest risk
with the aim of improving outcome. Such a strategy
could allow appropriate targeting of resources to at-risk
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pregnancies with subsequent improvements in maternal
and fetal outcomes.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Appendix S1 Biomarker assays.
Table S1 List of biomarker abbreviations and units
Table S2 Biomarker assay information
Table S3 Results of factor analysis: loadings of biomarkers on five largest factors (eigenvalues > 2) after
varimax rotation showing loadings > 0.6 only and uniqueness > 0.6
Table S4 Odds ratios derived from multiple logistic regression analysis of the five factors for prediction of
delivery of SGA infant in women presenting with suspected pre-eclampsia before 35 weeks’ gestation (odds
ratios are for a change of 1 SD in the factor score). Factors 3 and 4 (with significant odds ratios for prediction
of SGA infant < 3rd centile) were taken forward for further analysis
Table S5 Odds ratios derived from multiple logistic regression analysis of five factors for prediction of delivery
of SGA infant in women presenting between 35 + 0 and 36 + 6 weeks’ gestation with suspected pre-eclampsia
Table S6 STROBE checklist
Table S7 ROC curve areas (with 95% CI) for individual biomarkers to predict small-for-gestational age (SGA)
< 3rd and < 10th customized birth-weight centiles in women presenting with suspected pre-eclampsia before
35 weeks’ gestation
Table S8 Individual median biomarker concentrations (quartiles) in women presenting before 35 weeks’
gestation with suspected pre-eclampsia
Table S9 Predictive performance of individual indicators and their combinations, to predict delivery of
small-for-gestational age (SGA) < 10th customized birth-weight centile in 129 women presenting at 20 + 0 to
34 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound examination within 14 days
of enrolment
Table S10 Predictive performance of individual indicators and their combinations, to predict delivery of
small-for-gestational age (SGA) < 3rd customized birth-weight centile in 109 women presenting at 20 + 0 to
34 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound examination within 14 days
of enrolment, excluding those with known abnormal scan findings on day of enrolment
Table S11 Test performance statistics for individual indicators and their combinations to predict adverse
perinatal outcome in 109 women presenting before 35 weeks’ gestation with suspected pre-eclampsia, who
underwent ultrasound examination within 14 days of enrolment, excluding those with known abnormal scan
findings on day of enrolment
Table S12 Characteristics of 123 women presenting between 35 + 0 and 36 + 6 weeks’ gestation with
suspected pre-eclampsia (PE), according to subsequent birth weight of infant
Table S13 Delivery characteristics and maternal and neonatal outcome of 123 women presenting between
35 + 0 and 36 + 6 weeks’ gestation with suspected pre-eclampsia (PE), according to subsequent birth weight of
infant
Table S14 Individual biomarker areas under receiver–operating characteristics curves (AUCs) when sampled
between 35 + 0 and 36 + 6 weeks’ gestation
Table S15 Predictive performance of individual biomarkers and combinations (derived from logistic
regression) for prediction of small-for-gestational age (SGA) < 3rd centile and < 10th centile in 123 women
presenting between 35 + 0 and 36 + 6 weeks’ gestation with suspected pre-eclampsia
Table S16 Predictive performance of individual indicators and their combinations, to predict small-for-
gestational age (SGA) < 3rd customized birth-weight centile in 53 women presenting between 35 + 0 and
36 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound examination within 14 days
of enrolment
Table S17 Predictive performance of individual indicators and their combinations, to predict small-for-
gestational age (SGA) < 10th customized birth-weight centile in 53 women presenting between 35 + 0 and
36 + 6 weeks’ gestation with suspected pre-eclampsia, who underwent ultrasound examination within 14 days
of enrolment
Table S18 Predictive performance of individual indicators and their combinations, to predict adverse perinatal
outcome in 53 women presenting between 35 + 0 and 36 + 6 weeks’ gestation with suspected pre-eclampsia,
who underwent ultrasound examination within 14 days of enrolment
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